MTOR and breast carcinoma: CC-chemokine ligand 2 (CCL2) secreted by TAMs was revealed to activate the PI3K/AKT/mTOR pathway in breast cancer cells, thus induced resistance to tamoxifen treatment in breast cancer [16].